Year-over-year earnings per share growth for the last twelve months: quoinpharma.com (QNRX)

Quoin Pharmaceuticals Ltd (QNRX) - corporate logo

The biopharmaceutical business of Quoin Pharmaceuticals (QNRX) focuses on combating rare genetic skin pathologies, thereby assuming the binary risks inherent to the sector. The quarterly EPS change reflects market expectations, where the value 86.50 indicates the current metric. High patent potential and low competition ensure scalability, while experienced management focuses on achieving clinical milestones to drive shareholder value growth.

Quoin Pharmaceuticals Ltd (QNRX) Net earnings per share growth for the trailing year: for the period 07/04/2022 - 11/18/2026

Analytical breakdowns for Quoin Pharmaceuticals

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Analysis of all company metrics:Quoin Pharmaceuticals
Manufactured product of Quoin Pharmaceuticals

The efficiency of direct distribution for rare dermatological pathology drugs directly determines the net profit dynamics of Quoin Pharmaceuticals (QNRX). Analyzing the history of quarterly earnings per share changes, an investor can see the EPS percentage growth, which reflects the business's ability to scale revenues amid monetary stimulus; however, sharp spikes in this indicator may signal a risk of market overvaluation of the asset.

Key competitors

KRYS: Quarterly EPS earnings growth|APGE - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Arcutis Biotherapeutics, Inc.|Year-over-year earnings per share growth for the last 12 months VCEL (Vericel)|Year-over-year earnings per share growth for the last twelve months Oruka Pharma (ORKA)|Year-over-year net earnings per share change for the last twelve months Sanara MedTech|Quarterly EPS earnings growth DBVT (DBV Technologies SA)|Solesence Inc (SLSN) - Earnings per share growth in annualized terms for the last twelve months|DERM: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months FBRX (Forte Biosciences)|Empro Group (EMPG) - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year Sol-Gel Technologies Ltd. SLGL|Year-over-year net earnings per share growth for the last 12 months AXIL|Year-over-year net earnings per share growth for the last 12 months Medicus Pharma Ltd. (MDCX)|Quarterly EPS earnings growth VRCA|Year-over-year earnings per share growth rate for the last twelve months HOTH|Year-over-year earnings per share growth for the last twelve months biofrontera-us.com BFRI|Year-over-year earnings per one share growth for the last 12 months VYNE|SNOA - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Azitra Corporation AZTR|DRMA (Dermata) - Year-over-year net earnings per share growth for the last 12 months|Elevai Labs Inc. (ELAB) - Quarterly EPS earnings growth|RVNC (Revance Therapeutics, Inc.) - Quarterly EPS earnings growth